ENTITY
Antengene

Antengene (6996 HK)

55
Analysis
Health Care • China
Antengene is a global, R&D-driven, commercial-stage biotech company focused on discovering, developing, manufacturing, and commercializing first-in-class/best-in-class therapeutics for hematologic malignancies and solid tumors. Its pipeline includes in-house discovered programs like ATG-022 and ATG-101, and its lead commercial asset is XPOVIO® (selinexor). The company also developed the AnTenGager® T cell engager platform. Antengene is headquartered in Shanghai, China, and was founded in 2017.
more
Company Event • 19 Mar 2027 16:30 • Upcoming
Add To Calendar

H2 2026

Company Event • 21 Aug 2026 18:30 • Upcoming
Add To Calendar

H1 2026

Company Event • 20 Mar 2026 16:30 • Upcoming
Add To Calendar

H2 2025

Company Event • 04 Mar 2026 22:00 • Latest

Status update

Company Event • 22 Aug 2025 16:00 • Upcoming
Add To Calendar

H1 2025

x